CommercialCoverageMedium impact
Magnetic Sphincter Augmentation for the Treatment of Gastroesophageal Reflux Disease (GERD) 7.01.89
Excellus BlueCross BlueShield·Gastroenterology, General Surgery·Digestive System (Gastroenterology)
Effective date
Apr 17, 2025
We identified it
Jun 20, 2026
Summary
Excellus BlueCross BlueShield has established new coverage criteria for magnetic sphincter augmentation (LINX device) for GERD treatment, effective April 17, 2025. The policy requires patients to meet specific eligibility criteria including age 18+, failed PPI therapy for 6+ months, and absence of contraindications like BMI >35 or need for MRI >1.5 Tesla.
Action Required
By April 17, 2025: Billing team must review all LINX procedure authorizations to ensure patients meet new eligibility criteria including age requirements, 6-month PPI trial documentation, BMI restrictions, and contraindication screening. Update prior authorization checklists to include all specified requirements. Gastroenterology providers must complete shared decision-making documentation and comprehensive pre-operative evaluation including endoscopy, manometry, pH testing, and barium swallow.